Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Analysts

Shares of Guardant Health, Inc. (NASDAQ:GHGet Free Report) have been assigned a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the company, Marketbeat.com reports. Nineteen investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $48.21.

GH has been the topic of a number of recent analyst reports. Raymond James reaffirmed an “outperform” rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Guggenheim reaffirmed a “buy” rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Piper Sandler increased their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Barclays assumed coverage on Guardant Health in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company.

Check Out Our Latest Analysis on GH

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 2,768 shares of company stock valued at $98,798 over the last three months. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Guardant Health

A number of institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC raised its stake in shares of Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after purchasing an additional 230 shares in the last quarter. Summit Investment Advisors Inc. raised its position in Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock valued at $377,000 after acquiring an additional 391 shares in the last quarter. Arizona State Retirement System raised its position in Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock valued at $1,089,000 after acquiring an additional 403 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after acquiring an additional 796 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $42.55 on Friday. Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89. The stock has a fifty day moving average price of $40.87 and a 200 day moving average price of $31.89. The company has a market cap of $5.25 billion, a P/E ratio of -11.95 and a beta of 1.32.

Guardant Health (NASDAQ:GHGet Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, research analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

(Get Free Report

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.